Stephens & Co. Reiterates Overweight on West Pharmaceutical Servs, Maintains $360 Price Target
Benzinga Newsdesk 5 months ago
NewsPrice TargetReiterationAnalyst Ratings
Stephens & Co. analyst Steven Etoch reiterates West Pharmaceutical Servs (NYSE:WST) with a Overweight and maintains $360 price target.
Stephens & Co. analyst Steven Etoch reiterates West Pharmaceutical Servs (NYSE:WST) with a Overweight and maintains $360 price target.